PHARMABIZ.COM
Indoco Remedies to issue Bonus shares & sub-divide shares
Our Bureau, Mumbai
Thursday, March 22, 2012 14:05 Hrs. [IST]
Indoco Remedies Ltd, a Rs.475 crore plus pharm giant, has decided to issue
bonus share and sub divide its share of Rs.10 each. A meeting of the Board
of Directors of the company will be held on March 29, 2012 to consider bonus
share ratio and sub division. Indoco scrip moved up sharply by Rs.21 to
Rs.405 on BSE.
Indoco has a strong brand portfolio of 120 products in various therapeutic
segments, including high growth life style segments such as anti-infectives,
anti-diabetics, cardiovascular, ophthalmology, dental care, pain management
and respiratory. Top Indoco brands include Cyclopam, Vepan, Febrex Plus, ATM,
Sensodent–K, and Sensoform. Indoco has nine manufacturing facilities for
Formulations (Finished Dosage Forms) and Active Pharmaceutical
Ingredients (APIs) in India.
Indoco also has a state-of-the-art research centre at Navi Mumbai with over 200
scientists. With approval of its Finished Dosage facilities by the US-FDA,
Darmstadt-Germany, TGA Australia, MCC-South Africa and UK-MHRA, Indoco Remedies
has emerged as the most suitable partner and provider of Contract Research and
Manufacturing Services (CRAMS) to its customers globally.
Recently, Indoco Remedies has entered marketing agreement with Royal DSM N.V.,
for eight Active Pharmaceutical Ingredients (APIs) and the alliance came into
effect in January 2012. This marketing tie- up will leverage Indoco's product
development and cGMP (current Good Manufacturing Practices) compliant
manufacturing capabilities and DSM's market access.
|